Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Dr Frank Jessen
Department of Psychiatry, University of Cologne, Cologne, Germany
Prof. Dr Frank Jessen received his MD degree from the University of Saarland in 1995. After residencies in neuropathology at the University of Düsseldorf, and neurology and psychiatry at the University of Bonn, he was board certified as a psychiatrist and psychotherapist in 2002. He served from 2002-2010 as a consultant psychiatrist and head of clinical Alzheimer’s disease research at the Department of Psychiatry, University of Bonn. In 2010, he was appointed Professor of Clinical Dementia Research and deputy director of the Department of Psychiatry, University of Bonn. In 2015, he was appointed as a Professor of Psychiatry and Psychotherapy and director of the Department of Psychiatry, University of Cologne. Since 2010, he has been an associate researcher and group leader for Clinical Alzheimer Research at the German Center of Neurogenerative Diseases (DZNE).
Prof. Dr Jessen’s research focuses on prevention, early diagnosis and treatment of Alzheimer’s disease with expertise in neuropsychology, neuroimaging, epidemiology and genetics. He coordinated national and international multicenter observational studies and clinical trials. He is a member of the board of the Germany Psychiatric Association (DGPPN), for which he coordinates the German national guideline on the diagnosis and treatment of dementia (S3-guideline dementia).
Prof. Dr Frank Jessen discloses:
Fees for advice and presentations (2019–2023) from Abbie, AC Immune, Biogen, Danone/Nutricia, Eisai, Eli Lilly, GE Healthcare, Grifols, Janssen and Roche. Funding from BMBF, BZGA, DFG, DZNE, Eranet Neuron, Horizon 2020, IMI, IHI, Innovationfonds (GBA) and JPND. Membership of German Association of Psychiatry (DGPPN, member of the board), German Association of Biological Psychiatry (DGBP), German Association of Geriatrics (DGGPP), German Memory Clinic Network (DNG, Chair), European Alzheimer’s disease Consortium (EADC, Chair). Scientific advisory board member for German Alzheimer Association, Hirnliga Alzheimer Europe
Dr Atsushi Iwata
Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan
Dr. Atsushi Iwata received his medical degree from the University of Tokyo. After medical training and neurology residency at several hospitals, he became certified neurologist of Japanese society of Neurology. He then entered graduate school of medicine at the University of Tokyo. After receiving his Ph.D., he moved to Stanford University to study autophagy and protein aggregation as a pos-doc. He continued post-doctoral training back in the University of Tokyo and started his own laboratory from the year 2008.
Now a Project Associate Professor at the University of Tokyo, he serves as a general neurologist, as well as behavioral neurologist at the memory clinic. He is also conducting early detection of memory disorders in the medical check-up unit and conducting various clinical studies on Alzheimer’s disease at the University of Tokyo hospital.
His current research aims to elucidate pathomechanisms of sporadic neurodegenerative disorders through epigenetics and molecular biology. He is also involved in various clinical studies on Alzheimer’s disease and serving as a scientific board member for various pharmaceutical industries.
Dr Atsushi Iwata discloses:
Speaker fees and/or research grants from, and has been a member of advisory boards for Eisai and Shionogi. Speaker fees from and has been a member of advisory boards for Janssen Pharmaceuticals, Chugai-Roche, and Merck Sharp & Dohme. Speaker fees and research grants from Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, and One Pharmacreutical Co Ltd. Speaker fees from Kyowa Kirin Co Ltd, UCB Japan, and Eli Lilly. Research grants from AbbVie, Dainippon Sumitomo, the Japan Agency for Medical Research and Development, and the Japan Society for the Promotion of Science.
Dr Benoît Delatour
Centre national de la recherche scientifique (CRNS), Institut du Cerveau (ICM) Paris, France
Dr Benoît Delatour joined CNRS in 2002. His scientific interests were initially focused on the study of the functions of the hippocampal-prefrontal system in rodents that he addressed using multidisciplinary approaches (behavioural analysis of brain-lesioned animals; anatomical tracing studies to investigate topographical organization of neural systems). His research then rapidly evolved to the study of memory disorders related to pathological conditions (AD and associated pathologies such as Down’s syndrome, DS). Initiated by morphological analysis in postmortem tissue from human patients, this work presently relies on the in vivo study of mice models of the disease through neuroimaging, histological and behavioral approaches. Recent interest for DS has been driven by the obvious relationships that exist between AD and DS pathologies (at the neuropathological and genetic levels).
Dr Delatour’s research activity has always been carried out in a pluridisciplinary context, relying on active partnership with scientists developing various technical and conceptual expertise (molecular biology, small animal MR imaging, applied chemistry, biophysics etc.) and working in both academic and industrial backgrounds.
Dr Benoît Delatour discloses:
Speaker fees from Eli Lilly.
